Capmatinib for Lung Cancer
This trial is testing the side effects and best doses of two drugs, capmatinib and trametinib, when given together to treat patients with metastatic non-small cell lung cancer that has a mutation in the MET gene.
- Lung Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2020 Phase 2 trial • 18 Patients • NCT03647488
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What are the intended outcomes of this experiment?
"As outlined by the clinical trial sponsor, Novartis, this experiment will be gauging its primary outcome -- Proportion of participants with reported dose limiting toxicity (DLT) (Phase I) -- over a 12 month period. Secondary outcomes include: Proportion of participants with treatment-emergent adverse events (Phase I), Overall survival (OS) (Phase Ib), and Median Progression Free Survival (PFS) (Phase Ib). These are respectively defined as proportion of patients exhibiting Adverse Events graded via NCI CTCAE version 5.0 in Phase Ib; 1+ days from first drug dosage to death due to any"
Are there substantial risks associated with taking Capmatinib?
"As this is an early-stage trial, the safety of capmatinib has been assigned a score of 1. This implies that there exists minimal data on its efficacy and security."
How many participants will be part of this clinical trial?
"Correct. Details on clinicaltrials.gov confirm that this medical experiment, which was first listed on August 10th 2022, is still enrolling participants. 33 individuals will be accepted from 1 particular site."
Is recruitment still open for this experiment?
"Per clinicaltrials.gov, this medical research is currently recruiting patients who meet the criteria. This trial was first published on August 10th of 2022 and last modified five days later."